These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37046778)

  • 21. Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti-Epidermal Growth Factor Receptor Therapy.
    Maurel J; Alonso V; Escudero P; Fernández-Martos C; Salud A; Méndez M; Gallego J; Rodriguez JR; Martín-Richard M; Fernández-Plana J; Manzano H; Méndez JC; Zanui M; Falcó E; Gil-Raga M; Aparicio J; Feliu J; García-Albéniz X; Torres F; Rojo F; Bellosillo B; Mendiola M; Fernández V; Reig O; Claes B; Maertens G; Sablon E; Jacobs B; Montagut C
    JCO Precis Oncol; 2019 Dec; 3():1-16. PubMed ID: 35100697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Trial Protocol of Precision Medicine for Patients with RAS Wild Metastatic Colorectal Cancer Using Liquid Biopsy (RAS-liquid Study): A Prospective, Multicenter Observational Study.
    Matsuda A; Yamada T; Takahashi T; Hirata K; Nagasaka T; Ishimaru K; Sakamoto K; Koda K; Ishikawa T; Ishida H; Matsuda K; Kuramochi H; Yoshida Y; Sonoda H; Yoshida H
    J Anus Rectum Colon; 2022; 6(1):52-57. PubMed ID: 35128137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR.
    Pinheiro M; Peixoto A; Rocha P; Veiga I; Pinto C; Santos C; Pinto P; Guerra J; Escudeiro C; Barbosa A; Silva J; Teixeira MR
    Int J Colorectal Dis; 2022 Apr; 37(4):895-905. PubMed ID: 35303157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated
    Napolitano S; Martini G; Ciardiello D; Di Maio M; Normanno N; Avallone A; Martinelli E; Maiello E; Troiani T; Ciardiello F
    Front Oncol; 2022; 12():940523. PubMed ID: 35832541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer.
    Ciardiello D; Martini G; Famiglietti V; Napolitano S; De Falco V; Troiani T; Latiano TP; Ros J; Elez Fernandez E; Vitiello PP; Maiello E; Ciardiello F; Martinelli E
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33920531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.
    Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ
    Br J Cancer; 2015 Jun; 112(12):1888-94. PubMed ID: 25989278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients.
    Vidal J; Muinelo L; Dalmases A; Jones F; Edelstein D; Iglesias M; Orrillo M; Abalo A; Rodríguez C; Brozos E; Vidal Y; Candamio S; Vázquez F; Ruiz J; Guix M; Visa L; Sikri V; Albanell J; Bellosillo B; López R; Montagut C
    Ann Oncol; 2017 Jun; 28(6):1325-1332. PubMed ID: 28419195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.
    Thierry AR; El Messaoudi S; Mollevi C; Raoul JL; Guimbaud R; Pezet D; Artru P; Assenat E; Borg C; Mathonnet M; De La Fouchardière C; Bouché O; Gavoille C; Fiess C; Auzemery B; Meddeb R; Lopez-Crapez E; Sanchez C; Pastor B; Ychou M
    Ann Oncol; 2017 Sep; 28(9):2149-2159. PubMed ID: 28911069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
    Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
    Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Emergent Circulating Tumor DNA
    Kim TW; Peeters M; Thomas A; Gibbs P; Hool K; Zhang J; Ang AL; Bach BA; Price T
    Clin Cancer Res; 2018 Nov; 24(22):5602-5609. PubMed ID: 29898991
    [No Abstract]   [Full Text] [Related]  

  • 31. Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer.
    Klein-Scory S; Wahner I; Maslova M; Al-Sewaidi Y; Pohl M; Mika T; Ladigan S; Schroers R; Baraniskin A
    Front Oncol; 2020; 10():1115. PubMed ID: 32766143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic landscape and survival analysis of ctDNA "neo-
    Nicolazzo C; Magri V; Marino L; Belardinilli F; Di Nicolantonio F; De Renzi G; Caponnetto S; De Meo M; Giannini G; Santini D; Cortesi E; Gazzaniga P
    Front Oncol; 2023; 13():1160673. PubMed ID: 37064137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice.
    D'Onofrio R; Caputo F; Prampolini F; Spallanzani A; Gelsomino F; Bettelli S; Manfredini S; Reggiani Bonetti L; Carotenuto P; Bocconi A; Dominici M; Luppi G; Salati M
    Tumori; 2023 Aug; 109(4):387-393. PubMed ID: 36113407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer.
    Sagawa T; Sato Y; Hirakawa M; Hamaguchi K; Tamura F; Nagashima H; Fujikawa K; Okamoto K; Kawano Y; Sogabe M; Miyamoto H; Takayama T
    Front Oncol; 2023; 13():1203296. PubMed ID: 37434969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.
    Grasselli J; Elez E; Caratù G; Matito J; Santos C; Macarulla T; Vidal J; Garcia M; Viéitez JM; Paéz D; Falcó E; Lopez Lopez C; Aranda E; Jones F; Sikri V; Nuciforo P; Fasani R; Tabernero J; Montagut C; Azuara D; Dienstmann R; Salazar R; Vivancos A
    Ann Oncol; 2017 Jun; 28(6):1294-1301. PubMed ID: 28368441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
    Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
    J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
    Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
    Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
    Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
    Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients.
    Nicolazzo C; Barault L; Caponnetto S; Macagno M; De Renzi G; Gradilone A; Belardinilli F; Cortesi E; Di Nicolantonio F; Gazzaniga P
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33291569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients.
    Salvatore L; Bensi M; Vivolo R; Zurlo IV; Dell'Aquila E; Grande R; Anghelone A; Emiliani A; Citarella F; Calegari MA; Ribelli M; Basso M; Pozzo C; Tortora G
    Front Oncol; 2023; 13():1125013. PubMed ID: 36895480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.